Welcome to our dedicated page for RedHill Biopharma Ltd. SEC filings (Ticker: RDHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on RedHill Biopharma Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into RedHill Biopharma Ltd.'s regulatory disclosures and financial reporting.
RedHill Biopharma has filed an F-1 registration statement for a potential offering of up to 5,596,490 American Depositary Shares (ADSs) representing 55,964,900,000 ordinary shares. The offering relates to resale by Alumni Capital LP through an Any Market Purchase Agreement dated June 20, 2025.
Key offering details:
- Committed equity line of credit up to $10 million with Alumni Capital
- Each ADS represents 10,000 ordinary shares
- Includes 5,263,157 AMPA ADSs and 333,333 Commitment Warrant ADSs
- Purchase price varies based on VWAP: 82% for initial purchase, 90% for regular purchases, or 96% for forward purchases
The company is an Israeli-based foreign private issuer trading on Nasdaq under "RDHL". RedHill will not receive proceeds from ADS resales but will receive proceeds from warrant exercises. Alumni Capital is considered an underwriter and subject to a 4.99% ownership limitation. The last reported ADS price was $1.94 on June 24, 2025.
RedHill Biopharma has entered into an Any Market Purchase Agreement with Alumni Capital LP on June 20, 2025, enabling the company to sell up to $10 million in American Depositary Shares (ADSs). Key terms include:
- Initial tranche up to $1 million priced at 82% of lowest 5-day VWAP
- Subsequent regular purchases up to $500,000 or 60% of 5-day average trading volume at 90% of lowest 5-day VWAP
- Additional discretionary purchases up to $500,000 or 30% of same-day trading volume at 96% of lowest traded price
- Commitment Warrants issued to purchaser for 333,333 ADSs with $3.00 exercise price and 5-year term
The agreement includes a 4.99% ownership cap and requires SEC registration effectiveness. The arrangement provides RedHill with flexible funding options through June 30, 2026, subject to market conditions and company discretion.